- Conditions
- Major Depressive Disorder
- Interventions
- Zuranolone
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 12 Years to 17 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Flowood, Mississippi + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 10,564
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Breast Cancer
- Interventions
- Amrubicin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Fort Myers, Florida • Gainesville, Georgia + 11 more
- Conditions
- Hot Flashes
- Interventions
- Gabapentin Extended Release, Placebo
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- MRG004A
- Drug
- Lead sponsor
- Lepu Biopharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Orange, California • New York, New York • Canton, Ohio + 3 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 431
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more
- Conditions
- Cardiac Arrest
- Interventions
- Therapeutic Hypothermia, Therapeutic Normothermia
- Procedure · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 48 Hours to 18 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 136
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
- Conditions
- Psoriasis
- Interventions
- CTA018 cream
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more
- Conditions
- Atrial Fibrillation
- Interventions
- WATCHMAN FLX Implant, Market-approved OAC
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 70 more
- Conditions
- Postoperative Urinary Retention (POUR)
- Interventions
- Tamsulosin, Placebo
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Crohn's Disease, Ulcerative Colitis
- Interventions
- 25 mg Ontamalimab, 75 mg Ontamalimab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 103
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 88 more
- Conditions
- Osteoarthritis, Arthritis, Pain
- Interventions
- Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 91
- States / cities
- Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Interventions
- Infliximab (Remicade)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
- Conditions
- Graft Vs Host Disease
- Interventions
- Placebo, Abatacept
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Interventions
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib, Cirmtuzumab (RDR) plus ibrutinib, Cirmtuzumab plus ibrutinib, Ibrutinib alone
- Drug
- Lead sponsor
- Oncternal Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Duarte, California • La Jolla, California • Sacramento, California + 8 more
- Conditions
- Heart Failure, Left Ventricular Systolic Dysfunction
- Interventions
- Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 29 Days to 17 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
- Conditions
- Wheezing, Asthma
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more
- Conditions
- Epilepsy, Complex Partial
- Interventions
- Zonisamide
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
- Conditions
- Growth Hormone Disorder, Pituitary Dwarfism
- Interventions
- somatropin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 3 Years to 13 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 27
- States / cities
- Los Angeles, California • San Diego, California • Stanford, California + 23 more
- Conditions
- Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
- Interventions
- AXS-12 (Reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more
- Conditions
- Achondroplasia
- Interventions
- Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 15 Months and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2038
- U.S. locations
- 9
- States / cities
- Oakland, California • Torrance, California • Wilmington, Delaware + 6 more
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
- Interventions
- CHS-114, toripalimab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Atlanta, Georgia • Louisville, Kentucky + 9 more
- Conditions
- Suicide, Suicide, Attempted, Suicidal Ideation, Self Harm
- Interventions
- MI- Safety Plan, Texts messages, Monitoring, Portal follow-up, Booster call
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan • Cincinnati, Ohio
- Conditions
- Allergy, Peanut
- Interventions
- ligelizumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 55 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more